Medexus Pharmaceuticals Inc (TSE:MDP)
TSX:MDP
Top Page
Medexus Pharmaceuticals Inc
(TSX:MDP)
Select Model
Select Model
Rating:68Neutral
Price Target:
C$3.50
▲(13.64% Upside)
Action:ReiteratedDate:03/03/26
The score is primarily supported by improved financial quality—strong TTM free cash flow and a meaningfully deleveraged balance sheet—plus constructive price trend signals. It is held back by weak earnings-based valuation (negative P/E) and earnings-call risks around YoY revenue/earnings pressure and near-term launch investment drag despite improving GRAFAPEX adoption and guidance.
Positive Factors
Cash generation
Sustained TTM operating and free cash flow near $17M provides durable internal funding to reduce debt, fund launches and buybacks, and absorb temporary revenue variability. Strong cash conversion supports strategic flexibility and lowers reliance on external financing over the next 2–6 months.
Negative Factors
Revenue contraction risk
A meaningful YoY revenue decline driven by generic competition and loss/return of licensed products shows the business remains exposed to product-specific shocks. Structural revenue erosion from competitors or licensors forces reliance on successful launches to replace lost cash flows, heightening execution risk.
Read all positive and negative factors
Positive Factors
Negative Factors
Cash generation
Sustained TTM operating and free cash flow near $17M provides durable internal funding to reduce debt, fund launches and buybacks, and absorb temporary revenue variability. Strong cash conversion supports strategic flexibility and lowers reliance on external financing over the next 2–6 months.
Read all positive factors
Medexus Pharmaceuticals Inc (MDP) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$99.49M
Dividend YieldN/A
Average Volume (3M)46.68K
Price to Earnings (P/E)211.5
Beta (1Y)0.75
Revenue Growth2.14%
EPS Growth-83.06%
CountryCA
Employees82
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)0.00
Shares Outstanding32,300,380
10 Day Avg. Volume30,861
30 Day Avg. Volume46,683
Financial Highlights & Ratios
PEG Ratio1.50
Price to Book (P/B)1.19
Price to Sales (P/S)0.32
P/FCF Ratio1.95
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
C$6.00Price Target Upside94.81% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.02
Revenue Forecast (FY)C$100.34M
Medexus Pharmaceuticals Inc Business Overview & Revenue Model
Company Description
Medexus Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada and the United States. It focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, and allergy. The company's primar...
How the Company Makes Money
Medexus Pharmaceuticals generates revenue primarily through the sale of its pharmaceutical products, which include proprietary and licensed treatments for various conditions. The company has established key revenue streams through direct sales to ...
Medexus Pharmaceuticals Inc Earnings Call Summary
Earnings Call Date:Feb 11, 2026
(Q3-2026)
| % Change Since: |
Next Earnings Date:Jun 30, 2026
Earnings Call Sentiment Neutral
The call highlighted meaningful early commercial traction for GRAFAPEX (formulary uptake, reorder rates, improving patient demand and a FY26 revenue outlook of $11M–$12M), margin improvements, strong operating cash generation, reduced net debt and cost savings initiatives (IXINITY). Offsetting these positives were year-over-year declines in total net revenue, adjusted EBITDA and net income driven by Rupall generic competition, the return of Gleolan, and launch investments that have so far slightly exceeded GRAFAPEX product-level revenue. Management emphasized improving trends, cash flow strength, and financing flexibility that position the company to scale commercialization. Overall, the positives around GRAFAPEX momentum and liquidity improvements balance the near-term earnings and revenue headwinds, leading to a neutral assessment.Positive Updates
GRAFAPEX Early Commercial Adoption
32% of 180 U.S. transplant centers (57 institutions) have ordered GRAFAPEX and 77% of those centers have reordered; product-level patient demand rebounded strongly in January 2026 and product-level net revenue for the 9 months ending Dec 31, 2025 totaled $8.2M.
Negative Updates
YoY Net Revenue Decline
Total net revenue for fiscal Q3 '26 was $25.3M, down $4.7M or approximately -15.7% versus $30.0M in fiscal Q3 '25, driven in part by reduced Rupall sales and the return of Gleolan to its licensor.
Read all updates
Q3-2026 Updates
Positive
Negative
GRAFAPEX Early Commercial Adoption
32% of 180 U.S. transplant centers (57 institutions) have ordered GRAFAPEX and 77% of those centers have reordered; product-level patient demand rebounded strongly in January 2026 and product-level net revenue for the 9 months ending Dec 31, 2025 totaled $8.2M.
Read all positive updates
Company Guidance
Management guided that GRAFAPEX will be accretive to quarterly operating cash flow starting in fiscal Q4 ’26 and is expected to generate product‑level net revenue of $11–$12 million for fiscal 2026; through the nine months ended Dec 31, 2025 they recognized $8.2M of GRAFAPEX product‑level revenue versus $8.5M invested in the launch year‑to‑date, Q3 ’26 product‑level net revenue was $2.0M (underlying patient demand $2.6M), and they expect patient demand in fiscal Q4 ’26 of roughly $3–$4M (prior quarters: Q1 $2.2M, Q2 $2.1M, Q3 $2.6M) which, given wholesaler inventory, implies Q4 product‑level net revenue of $3–$4M; adoption metrics include 32% of the 180 U.S. transplant centers (57 centers) having ordered with a 77% reorder rate, roughly one‑third on formulary/one‑third under review/one‑third in process, and an adult/pediatric split of ~85%/15% (Medicare NTAP add‑on ≈ $21,000 covering ~30% of adult patients); SG&A related to GRAFAPEX is expected to rise modestly back toward $3–$4M and nearer $4M in fiscal ’27; company‑level Q3 results and balance‑sheet metrics cited alongside this guidance were: net revenue $25.3M (vs $30.0M y/y), gross profit $13.6M (gross margin 53.6% vs 50.7% y/y), adjusted EBITDA $4.5M (vs $5.8M), operating income $1.7M (vs $2.1M), net income $0.1M (vs $0.7M), operating cash flow $7.8M (vs $6.7M), average cash from operations $4.3M/quarter since launch, cash on hand $15M (Dec 31, 2025), net debt $10.4M (down from $13.2M Mar 31, 2025), 201,500 shares repurchased, a new credit facility that reduced quarterly principal repayments from $3.3M to $0.5M, a $1.2M committed IXINITY process investment (to be paid in fiscal ’26) and a 30% reduction in IXINITY product‑level COGS since fiscal Q1 ’21.Medexus Pharmaceuticals Inc Financial Statement Overview
Summary
Income Statement
63
Positive
Balance Sheet
68
Positive
Cash Flow
79
Positive
| Breakdown | TTM | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 99.43M | 108.33M | 113.05M | 108.10M | 76.70M | 79.66M |
| Gross Profit | 53.57M | 56.58M | 59.51M | 60.04M | 37.93M | 42.01M |
| EBITDA | 17.35M | 16.81M | 19.28M | 16.14M | 15.16M | -23.61M |
| Net Income | -240.45K | 2.25M | -214.00K | 1.22M | -2.88M | -28.26M |
Balance Sheet | ||||||
| Total Assets | 154.98M | 171.84M | 155.73M | 161.33M | 139.22M | 148.51M |
| Cash, Cash Equivalents and Short-Term Investments | 14.97M | 23.97M | 5.25M | 13.07M | 10.02M | 18.70M |
| Total Debt | 25.35M | 37.18M | 49.90M | 94.72M | 54.86M | 56.40M |
| Total Liabilities | 102.77M | 119.69M | 125.41M | 187.70M | 151.82M | 130.50M |
| Stockholders Equity | 52.21M | 52.14M | 30.32M | 22.45M | 17.79M | 18.02M |
Cash Flow | ||||||
| Free Cash Flow | 17.16M | 21.31M | 18.45M | -1.81M | -8.89M | -5.72M |
| Operating Cash Flow | 17.36M | 24.03M | 18.71M | -1.44M | -1.18M | 5.04M |
| Investing Cash Flow | -11.48M | -6.00M | -3.48M | -1.72M | -8.20M | -11.70M |
| Financing Cash Flow | 418.00K | 796.00K | -23.05M | 6.41M | 663.00K | 18.68M |
Medexus Pharmaceuticals Inc Technical Analysis
Neutral
3.08
Price Trends
2.96
Positive
2.86
Positive
2.88
Positive
Market Momentum
0.04
Positive
50.80
Neutral
35.56
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:MDP, the sentiment is Neutral. The current price of 3.08 is below the 20-day moving average (MA) of 3.13, above the 50-day MA of 2.96, and above the 200-day MA of 2.88, indicating a neutral trend. The MACD of 0.04 indicates Positive momentum. The RSI at 50.80 is Neutral, neither overbought nor oversold. The STOCH value of 35.56 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for TSE:MDP.
Medexus Pharmaceuticals Inc Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
80 Outperform | C$169.01M | 15.91 | 23.25% | 1.60% | 22.22% | 25.50% | |
68 Neutral | C$99.49M | 211.50 | 0.87% | ― | 2.14% | -83.06% | |
59 Neutral | C$54.49M | -6.17 | -21.73% | ― | 43.56% | -349.41% | |
54 Neutral | C$11.69M | -2.12 | -18.39% | ― | 24.30% | -68.60% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | C$21.43M | -5.29 | -256.01% | ― | ― | ― | |
42 Neutral | C$64.56M | -16.32 | ― | ― | -62.34% | 9.80% |
* Healthcare Sector Average
TSE:MDP
Medexus Pharmaceuticals Inc
3.08
0.66
27.27%
TSE:MPH
Medicure
1.12
0.33
41.77%
TSE:RX
Biosyent
14.70
3.73
33.99%
TSE:VEXT
Vext Science
0.22
0.04
22.22%
TSE:VM
Voyageur Pharmaceuticals
0.12
-0.05
-29.41%
TSE:BNXT
BioNxt Solutions
0.53
-0.01
-1.85%
Medexus Pharmaceuticals Inc Corporate Events
Financial DisclosuresRegulatory Filings and Compliance
Medexus Sets Date for Q3 2026 Earnings Call and Webcast
Neutral
Feb 3, 2026
Medexus Pharmaceuticals has scheduled a conference call on February 12, 2026, to discuss its financial results for the third fiscal quarter ended December 31, 2025, with financial statements and management’s discussion and analysis to be fil...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.